US FDA issues complete response letter for proposed biosimilar pegfilgrastim

Biocon

10 October 2017 - The U.S. FDA has issued a complete response letter for Mylan´s biologics license application for MYL-1401H, a proposed biosimilar pegfilgrastim. 

This product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan.

The letter relates to the pending update of the BLA with certain CMC data from facility re-qualification activities post recent plant modifications. The letter did not raise any questions on biosimilarity, pharmacokinetic/pharmacodynamic data, clinical data or immunogenicity.

Read Biocon press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Biosimilar